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Abstract
Background We showed previously that nuclear localiza-
tion of the androgen receptor (AR) and expression of the
androgen-responsive gene FK506-binding protein 5
(FKBP5) in esophageal adenocarcinoma (EAC) tissues
were associated with decreased patient survival, suggesting
a role for androgens in this cancer.
Aim To investigate the effect of the AR ligand 5a-dihy-
drotestosterone (DHT) on AR-expressing EAC cell lines
in vitro.
Methods and Results In tissue resection specimens from
EAC patients, FKBP5 expression was positively associated
with proliferation as measured by Ki-67 expression. We
stably transduced AR into three AR-negative EAC cell
lines, OE33, JH-EsoAd1, and OE19, to investigate andro-
gen signaling in vitro. In the AR-expressing cell lines,
10 nM DHT, the concentration typically used to study AR
signaling, induced changes in the expression of androgen-
responsive genes and inhibited proliferation by inducing
cell cycle arrest and senescence. At lower DHT concen-
trations near the half maximal inhibitory concentration
(IC50), the AR-expressing cell lines proliferated and there
were changes in the expression of androgen-responsive
genes. In direct co-culture with cancer-associated fibrob-
last-like PShTert myofibroblasts, 10 nM DHT induced
changes in the expression of androgen-responsive genes
but did not inhibit proliferation.
Conclusions This is the first study to show that EAC cell
lines respond to androgen in vitro. Proliferation together
with the expression of androgen-responsive genes was
dependent on the concentration of DHT, or the presence of
a permissive microenvironment, consistent with observa-
tions in the tissues. These findings are consistent with a role
for androgen signaling in EAC.
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Introduction
The incidence of esophageal adenocarcinoma (EAC) has
increased rapidly over recent decades in Western countries
[1–5]. It has a dismal prognosis, with around 65% of
patients unsuitable for surgery at the time of diagnosis and
an overall five-year survival rate of less than 15% [6, 7]. The
major risk factors for EAC are gastro-esophageal reflux
disease and obesity, leading to the only described precursor
lesion for this cancer, Barrett’s esophagus. This cancer has
one of the highest male-to-female ratios reported for cancers
of non-reproductive organs, ranging from 7–10 to 1
[1, 2, 4, 6, 8–11], significantly higher than for the major risk
factors. The gender difference appears to result from an
approximate 20-year delay in onset in females of Barrett’s
esophagus [12] and EAC [13]. These observations are
consistent with a role for the sex steroid hormones in the
biology of this cancer, with their concentrations differing
between males and females, and changing over the lifespan.
The most important sex hormones in males are the
androgens, and the most predominant androgen is testos-
terone. Testosterone passes through the cell membrane and
into the cytoplasm where it, or its more physiologically
effective metabolite 5a-dihydrotestosterone (DHT), binds
to and activates the androgen receptor (AR). Activated AR
translocates from the cytoplasm into the nucleus and binds
to androgen response elements in the genome, influencing
the transcription of androgen-responsive genes. The nature
of the response can be modified by the relative abundance
of multiple co-regulators (both co-activators and core-
pressors) [14].
We previously reported the immunostaining of EAC
tissues for AR and the androgen-responsive gene FK506-
binding protein 5 (FKBP5) [15]. We detected AR in the
cancer cells of 75 of 77 cases, and in 70 it was nuclear. The
expression of FKBP5 was observed in 64% of cases and
only when the AR was nuclear. There was a significant
association between nuclear AR and FKBP5 expression
and decreased survival.
Given the association between AR localization, FKBP5
expression, and poor survival, we sought suitable cell lines
to investigate the effect of androgen signaling on the
behaviors of EAC cells. All available cell lines were AR
negative, probably due to loss of AR expression during the
establishment of cell lines from tissues [15]. We therefore
stably transduced three EAC cell lines with AR. The aim of
this study was to investigate factors that affect the growth
of and gene expression in AR-expressing EAC cell lines in
response to androgen.
Methods
Immunohistochemistry for Ki-67 and FKBP5
Tissue microarrays (TMAs) composed of one or more
representative cores of EAC were constructed as described
previously [16]. Sequential sections consisting of cores
from 74 cases were immunostained for FKBP5 [15] and
Ki-67 [17]. Cores were scored as the percent of epithelial
cells that expressed FKBP5 or Ki-67 as follows: 0, nega-
tive; 1, \ 5% (rare); 2, \ 25%; 3, [ 25% \ 75%; 4,
[ 75%. The median score for FKBP5 and Ki-67 (Ki-67
index) was determined for multiple cores from each case.
Cell Culture
The EAC cell lines OE33, JH-EsoAd1, and OE19 [18, 19]
were obtained from the ATCC, Johns Hopkins University,
and Sigma-Aldrich, respectively. They were stably trans-
duced with AR and green fluorescent protein (GFP), or with
GFP only [15]. At least six single-cell clones were estab-
lished from each AR-transduced cell line, and the clone
expressing the lowest amount of AR, as determined by
western immunoblot, was used for all experiments unless
otherwise stated. The cell lines expressing AR and GFP are
referred to as OE33-AR, JH-AR, and OE19-AR, respec-
tively. The EAC cell lines were maintained in androgen-
depleted growth medium (stripped medium) consisting of
phenol red-free RMPI-1640 containing L-glutamine (Life
Technologies, Eugene, OR, USA), supplemented with 10%
dextran charcoal stripped fetal bovine serum (Equitech-Bio,
Inc., Kerrville, TX, USA), 200 U/mL penicillin, and 200 lg/
mL streptomycin (Life Technologies). Strippedmediumwas
used for experiments unless stated otherwise.
The PShTert myofibroblasts [20–22] were stably trans-
duced with the SFG-RFP/Rluc construct to express red
fluorescent protein (RFP) [23]. Neonatal foreskin fibrob-
lasts (NFFs) and PShTert myofibroblasts were used
between passages 10 and 20. Fibroblasts were maintained
in DMEM containing L-glutamine (Life Technologies),
supplemented with 10% fetal bovine serum (FBS; Sigma-
Dig Dis Sci (2017) 62:3402–3414 3403
123
Aldrich, St Louis, MO, USA), 200 U/mL penicillin, and
200 lg/mL streptomycin (Life Technologies).
Direct Co-culture
The NFFs and PShTert myofibroblasts were cultured in
stripped medium overnight, seeded at 4 9 105 cells per
well into six-well plates (BD Biosciences, Franklin Lakes,
NJ, USA), and then incubated for 48 h to form confluent
monolayers. Next, OE33-ARs were seeded at 1 9 105 cells
per well either in monoculture or in direct co-culture with
the fibroblasts. The following day (day 0), and every 48 h
thereafter, the medium was replaced with stripped medium
supplemented with vehicle (0 nM DHT; 0.1% ethanol) or
10 nM DHT. Cells were harvested on day 6 of treatment,
unless stated otherwise.
Translocation of Androgen Receptor
To establish direct co-cultures, fibroblasts were cultured in
stripped medium overnight, then seeded at 8 9 104 fibrob-
lasts per well in eight-well Lab-Tek Chamber Slides
(Thermo Fisher Scientific, Rochester, NY, USA), and incu-
bated for 48 h. Next, OE33-ARs (2 9 104 cells per well)
were added to the wells, followed by overnight incubation.
The medium, supplemented with vehicle or 10 nM DHT
(day 0), was replaced then and every 48 h for 6 days.
Following treatment, the cells were washed in Dul-
becco’s phosphate-buffered saline (DPBS; Life Technolo-
gies), fixed in methanol on ice for 5 min, and air-dried. The
cells were blocked with 10% normal goat serum (Dako,
Glostrup, Denmark) in DPBS for 20 min and labeled with
rabbit antihuman AR polyclonal IgG (clone N-20; 1 lg/mL
in 1.5% goat serum; Santa Cruz Biotech Inc., Santa Cruz,
CA, USA) for 1 h, followed by incubation with Alexa
Fluor 568 goat anti-rabbit IgG (2 lg/mL in 1.5% goat
serum; Molecular Probes by Life Technologies) for
45 min. Nuclei were stained with 1 lg/mL 40, 6-diamidino-
2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) in
DPBS for 15 min. Slides were mounted in fluorescent
mounting medium (Dako) and stored at 4 C in darkness.
Images were captured using a Zeiss LSM 700 confocal
microscope.
Cell Proliferation
To measure cell proliferation, 1 9 103 cells per well were
seeded in 96-well plates and cultured for 48 h. The cells
were then treated with either vehicle or various concen-
trations of DHT for 6–12 days, depending on the cell line.
The cells were next fixed in 10% neutral buffered formalin
for 30 min, stained for 10 min with 1% crystal violet
(Sigma-Aldrich) in 2% ethanol, washed eight times in
distilled water, and then air-dried overnight. The crystal
violet was eluted using 10% acetic acid and gentle rotation
of the plates. The absorbance of the eluent was measured at
595 nM using a FLUOstar Optima microplate reader
(BMG Labtech, Ortenberg, Germany). To determine whe-
ther growth inhibition with DHT was mediated via AR,
OE33-ARs were seeded into six-well plates (1 9 105 cells
per well) and cultured for 48 h. The cells were treated for
6 days with 10 nM DHT and either vehicle (0.15% dime-
thyl sulfoxide; Sigma-Aldrich) or 15 lM enzalutamide
(MedChem Express, Princeton, NJ, USA).
Cell division of OE33-AR was measured by dye dilu-
tion, using CellTrace Violet (CTV; Life Technologies).
Cells were seeded in six-well plates (3 9 104 cells per
well) and incubated for 24 h. Wells for time 0 were then
fixed in 4% paraformaldehyde. In the other wells, the
medium was replaced daily, supplemented with either
vehicle or DHT at around the half maximal inhibitory
concentration (IC50; 0.06 and 0.1 nM) or 10 nM. Other
wells were fixed with 4% paraformaldehyde 1, 3, or 5 days
following. The amount of CTV in the cells was measured
using a FACSCanto II (BD Biosciences) with BD FACS-
Diva software. Cell doublets were excluded by doublet
discrimination, based on nonlinearity of forward scatter
and side scatter area versus height plots. Cells were gated
based on GFP-positivity, and the median CTV intensity of
this population determined using FlowJo software version
8.8.7 (Ashland, OR, USA).
Quantitative Real-Time Reverse Transcription PCR
(qRT-PCR)
Total RNA was isolated from cells using TRIzol, and 1 lg
was reverse-transcribed using the iScript cDNA Synthesis
Kit (Bio-Rad Laboratories, Hercules, CA, USA) in a final
reaction volume of 20 lL. Gene expression was deter-
mined by quantitative real-time reverse transcription
polymerase chain reaction (qRT-PCR) using iQ SYBR
Green Supermix (Bio-Rad Laboratories) in a final reaction
volume of 10 lL, containing 0.1 lL of cDNA, and a final
concentration of 0.2 lM of each forward and reverse pri-
mer (Supplementary Table S1). Reactions were performed
using a CFX96 (Bio-Rad Laboratories) at 95 C for 3 min,
then 40 cycles of 95 C for 15 s, 60 C for 15 s, and 72 C
for 30 s, followed by a final extension of 72 C for 1 min.
Products were melted to confirm specificity. Normalized
fold expression was calculated using actin beta (ACTB) as
the reference gene.
Cell Cycle Analysis
OE33-ARs were seeded at 1 9 105 cells per well in
stripped medium in six-well plates and incubated for 24 h.
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The medium was then replaced daily, supplemented with
either vehicle or 0.06, 0.1, or 10 nM DHT. Wells were
harvested at 0, 24, 48, or 72 h. The cells were washed,
resuspended in DPBS, and fixed with a final concentration
of 70% ice-cold ethanol. The cells were pelleted, resus-
pended with 0.25% Triton X-100 (Sigma-Aldrich) in
DPBS, and incubated for 2 h with 25 lg/mL propidium
iodide (Sigma-Aldrich) and 40 lg/mL bovine pancreas
ribonuclease A (Sigma-Aldrich) in DPBS. The DNA con-
tent of single cells was measured using a FACSCanto II.
The percentages of cells in each cell cycle phase and in
sub-G1 were calculated using BD FACSDiva software.
Confocal Microscopy
To assess morphology, OE33-AR (1.72 9 103), JH-AR
(5.73 9 103), or OE19-AR (5.73 9 103) cells were seeded
into 96-well l-plates (Ibidi, Martinsried, Germany) in
stripped medium supplemented with either vehicle or
10 nM DHT replaced daily for 3 days. For direct co-cul-
tures, NFFs were labeled using the CellTrace Violet (CTV)
Cell Proliferation Kit according to the manufacturer’s
protocol (Life Technologies). Fibroblasts were seeded at
1.14 9 104 per well, and OE33-ARs were seeded over-
night at 1.43 9 103 cells per well, in either monoculture or
overlying fibroblasts followed by treatment with vehicle or
10 nM DHT for 6 days, with medium replaced every 48 h.
Images were captured using a Zeiss LSM 700 confocal
microscope with Zen2012 SP1 (black edition) software
version 8.1.
Senescence-Associated Beta-Galactosidase Assay
Cells were seeded in 24-well plates at 2 9 103 cells per
well for OE33 and OE33-AR and 3 9 103 cells per well for
JH-AR and OE19-AR, followed by 48-h incubation. The
culture medium was then replaced daily with fresh medium
supplemented with vehicle or DHT (IC50s and 10 nM). On
days 0, 1, 3, and 5 for OE33 and OE33-AR and 0, 4, 6, and
8 for JH-AR and OE19-AR, wells were stained with the
Senescence Cells Histochemical Staining Kit (Sigma-
Aldrich). The percentage of senescence-associated beta-
galactosidase (SA-b-gal) positive cells was calculated from
a count of 200 cells.
Statistics
The statistical software used was Prism 6.0d for Macintosh
(GraphPad Software, San Diego, CA, USA). Proliferation
dose–response curves were fitted, and the IC50 determined
by nonlinear regression analysis. Data are the mean ± SD
of a single experiment reproduced in triplicate with p val-
ues determined by parametric unpaired Student’s t test
assuming equal standard deviations (SD), unless stated
otherwise. Differences were considered significant when
the two-tailed p value was B 0.05.
Results
EAC Tissues with a High Percentage of FKBP5-
Positive Cells Had a High Proliferation Index
Previously, we reported that the expression of FKBP5, a
surrogate marker for androgen signaling, was associated
with reduced survival in EAC [15]. To determine the
relationship between AR signaling and tumor growth
in vivo, we measured the percentage of FKBP5 positive
cells and the Ki-67 proliferation index in immunostained
EAC resection specimens (Supplementary Fig. S1). There
was a positive correlation between the FKBP5 expression
and the proliferation index (nonparametric Spearman cor-
relation r = 0.37, 95% confidence interval 0.1533–0.5628;
p = 0.0010), with the proliferation index significantly
higher in those tissues with higher FKBP5 expression
(Fig. 1; p = 0.0002).
DHT Inhibited Proliferation of AR-Expressing EAC
Cell Lines In Vitro
Expression of AR protein was confirmed in the three EAC
cell lines stably transduced with AR, OE33-AR, JH-AR,
and OE19-AR, by western immunoblot (Supplementary
Fig. S2a) and immunocytochemistry (Supplementary
Fig. S2b). In the absence of DHT, AR immunoreactivity
Fig. 1 Ki-67 proliferation indices in EAC resection tissues with low
(B 2) or high ([ 2) FKBP5 expression. Tissue microarrays were
immunostained and scored as the percentage of epithelial cells that
expressed FKBP5 or Ki-67 as follows: 0, negative; 1,\ 5% (rare); 2,
\ 25%; 3,[ 25%\ 75%; 4,[ 75%. Data are the median score of
cores from each case. p value by Mann–Whitney U test
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was seen by confocal microscopy to be moderate in the
cytoplasm and mild to moderate in the nucleus. Exposure
to 10 nM DHT induced complete nuclear localization of
the AR, confirming that the transduced AR was function-
ally responsive to androgen.
In the AR-negative cell lines, exposure to DHT at
concentrations up to 100 nM did not significantly alter
proliferation (data not shown). The dose–response curves
for each of the AR-expressing lines, given a single dose of
DHT at the start of culture, are shown in Fig. 2a. The
concentration of DHT used in most reported studies of AR
signaling in vitro is 10 nM, which completely inhibited
proliferation of OE33-AR and JH-AR, and almost com-
pletely of OE19-AR. The IC50s were 0.09, 0.26, and
1.3 nM for OE33-AR, JH-AR, and OE19-AR, respectively.
To determine whether the differences in the DHT dose–
response curves between the cell lines were due to the
amount of AR expressed, we compared, within each of the
transduced lines, clones with the highest and lowest
expression of AR and found no significant differences in
the DHT dose–response curves (data not shown). We also
observed the same or similar dose–response for the
uncloned OE33-AR. The addition of the AR antagonist
enzalutamide (15 lM) completely blocked the growth
inhibition of the AR-expressing cells induced by 10 nM
DHT, confirming that the anti-proliferative effect was
mediated by the AR (p\ 0.0001; Fig. 2b).
For subsequent experiments, we used two concentra-
tions of DHT near the IC50 (0.06 and 0.1 nM for OE33-
AR, 0.25 and 0.5 nM for JH-AR, and 0.5 and 1.0 nM for
OE19-AR), as well as 10 nM. We next examined the
possibility that proliferation may differ with daily
Fig. 2 Effect of DHT on the proliferation of AR-expressing EAC cell
lines. a Dose–response curves for the proliferation of AR-expressing
EAC cells grown for 6–12 days with vehicle or tenfold serial dilutions
of DHT. Proliferation was measured by crystal violet assay. Data are
the mean ± SD of six replicates, and the corresponding nonlinear
regression curve, from a representative experiment for each cell line.
b The effect of 15 lM enzalutamide on the proliferation of OE33-AR
treated with 10 nM DHT
Fig. 3 Effect of single compared to daily doses of DHT on OE33-AR
growth and FKBP5 expression. a Dose–response curves for the
proliferation of OE33-AR grown for 5 days with vehicle or twofold
serial dilutions of DHT given as a single dose or replaced daily. Data
are the mean ± SD of six replicates, and the corresponding nonlinear
regression curve, from a representative experiment. b Normalized
fold FKBP5 expression after 3 days culture with a single dose or daily
replacement of vehicle or DHT. Data are the mean ± SD of triplicate
reactions for three biological replicates
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replenishment of DHT compared to a single treatment at
the start of the culture. The results in Fig. 3a show the DHT
dose–response curves for OE33-AR. These were similar
whether the DHT was given as a single treatment or daily
in fresh medium, with IC50s of 0.08 and 0.06 nM,
respectively.
DHT Induced Androgen-Responsive Gene
Expression in AR-Expressing Cell Lines
In preliminary studies, we found that cell lines cultured
with a single dose of 10 nM DHT expressed high levels of
the androgen-responsive gene FKBP5, even though pro-
liferation was inhibited. At lower concentrations of DHT,
around the IC50, there was partial inhibition of growth but
no, or very low, FKBP5 expression. This appeared to
conflict with our immunostains of resection tissues where
we frequently measured FKBP5 and Ki-67 expression
together.
We therefore compared the effect of a single dose to
daily replenishment of DHT on the induction of the
androgen-responsive gene FKBP5 in OE33-AR (Fig. 3b).
A single dose induced an increase in FKBP5 expression
compared to vehicle of 1.2-fold for 0.06 nM DHT
(p = 0.002), 2.2-fold for 0.1 nM (p = 0.0004), and 22-fold
for 10 nM (p = 0.0005) after 3 days of culture. In contrast,
when the DHT was replenished daily, the increase in
FKBP5 expression compared to vehicle was twofold for
0.06 nM (p = 0.03), fourfold for 0.1 nM (p\ 0.0001), and
16-fold for 10 nM (p = 0.0002.). The increases in FKBP5
expression for daily compared to single dosing were sig-
nificantly greater for 0.06 and 0.1 nM DHT (p = 0.02 and
p\ 0.0001, respectively), but not for 10 nM (p = 0.639).
Daily dosing, which would be expected to more closely
mimic in vivo conditions, with concentrations of DHT
around the IC50, permitted growth and induced significant
expression of FKBP5.
Next, we measured the expression of known androgen-
responsive genes in each of the three AR-expressing cell
lines at the different concentrations of DHT. We found that
the pattern of response was similar between the cell lines,
although there were differences in the fold increases
(Supplementary Fig. S3).
DHT Inhibited Cell Division and Induced Cell Cycle
Arrest and Cell Senescence in AR-Expressing Cells
To understand better the inhibition of growth, we analyzed
the effect of DHT on cell division, cell cycle arrest, and
cell senescence. Cell division in OE33-AR, as measured by
the intracellular dilution of CTV, was inhibited after 3 and
5 days of culture (Fig. 4a). The median CTV content at day
0 was 25,724 fluorescence units (FU). After 5 days of
treatment with vehicle, it was reduced to 535 FU. In con-
trast, after 5 days of treatment with 0.06, 0.1, and 10 nM
DHT the median CTV content was 621 FU, 930 FU, and
5760 FU, respectively, indicating that there was less cell
division as the concentration of DHT increased.
Next, we measured the cell cycle phase distribution by
flow cytometry following 3 days of culture. The results are
shown in Fig. 4b. There were no significant changes in the
proportion of cells in each phase of the cell cycle following
treatment with 0.06 nM DHT. Compared to vehicle, there
was a 19% (p = 0.006) and 52% increase (p = 0.0004) in
the proportion of cells in the G0/G1 phase following
treatment with 0.1 and 10 nM DHT, respectively, a 34%
(p = 0.0004) and 47% (p = 0.003) decrease in cells in the
G2/M phase, and no difference and a decrease of 51%
(p = 0.009) in the S phase. There was no sub-G1 popula-
tion with any of the concentrations, suggesting that DHT
did not induce cell death. The expression of E2F1, a
transcriptional activator necessary for progression through
the G1/S transition, was significantly inhibited with 0.1 nM
(p = 0.0004) and 10 nM (p = 0.0002) of DHT by day 3 of
culture (Fig. 4c).
Using time-lapse confocal microscopy, we observed that
each of the three AR-expressing cell lines underwent
extensive morphological changes over 3 days in mono-
culture with 10 nM DHT (Fig. 4d). The cells became dis-
cohesive, enlarged, and flattened, with the appearance of
many large cytoplasmic holes. There was no microscopic
evidence of extensive cell death. Because these changes
were suggestive of senescence, we stained cultures for the
senescence marker, senescence-associated beta-galactosi-
dase (SA-b-gal). There was a concentration and time-de-
pendent increase in the percentage of SA-b-gal stained
cells over the duration of culture in each of the three cell
lines, which was most pronounced in OE33-AR and least in
OE19-AR (Fig. 4e). Together these results demonstrated
that DHT inhibited the proliferation of AR-expressing EAC
cell lines in vitro by inducing growth arrest and senescence
in a dose-dependent manner.
cFig. 4 Effect of treatment with vehicle or DHT on cell division, cell
cycle stage, morphology, and senescence in AR-expressing EAC
cells. OE33-ARs were treated with vehicle or DHT at IC50 doses or
10 nM. a Division of OE33-AR monitored by CellTrace Violet dye
dilution on days 1, 3, and 5 post-treatment (n = 3). The peaks
represent different generations of cells. b Cell cycle distribution and
c normalized E2F1 expression (mean ± SD) on day 3 following
treatment of OE33-AR (n = 3). d Fluorescent micrographs of OE33-
AR, JH-AR and OE19-AR treated for 3 days with vehicle or 10 nM
DHT. Scale bar is 75 lM. e Percentage of OE33-AR, JH-AR, and
OE19-AR positive for senescence-associated beta-galactosidase (SA-
b-gal) on various days post-treatment with vehicle or DHT. Data are
the mean ± SD of pooled replicate experiments (OE33-AR, n = 3;
JH-AR and OE19-AR, n = 2)
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The Effect of Direct Co-culture with Fibroblasts
We next explored the possibility that fibroblasts, the major
cell population within the tumor microenvironment, which
are known to influence the response of tumor cells to drugs
[24], might modify the response of AR-expressing EAC
cells to androgens. Normal neonatal foreskin fibroblasts
(NFFs) and PShTert myofibroblasts representative of can-
cer-associated fibroblasts were used.
The morphology of OE33-AR in monoculture and direct
co-culture with NFFs, vehicle, or 10 nM DHT is shown in
Fig. 5a. With vehicle, there was no apparent microscopic
difference between OE33-AR grown in monoculture or in
direct co-culture with NFFs. They formed numerous clus-
ters of cells with distinct cell borders, polygonal shape, and
well-defined nuclei. With 10 nM DHT, growth of OE33-
AR was inhibited in both the monoculture and the NFF
direct co-culture. The OE33-AR were enlarged and con-
tained numerous refractile, round bodies devoid of obvious
structural content under phase microscopy and lacking GFP
under fluorescence microscopy. This effect of DHT on
OE33-AR growth in monoculture and direct co-culture
with NFFs was also reflected in the cell counts shown in
Fig. 5b.
In relation to the co-culture of OE33-AR with cancer-
associated fibroblast-like PShTert myofibroblasts, there
were no apparent microscopic differences between the
monoculture and the direct co-culture with the myofi-
broblasts, either with vehicle or with 10 nM DHT
(Fig. 5a), and no differences between the counts of OE33-
AR grown with vehicle compared to 10 nM DHT in the
direct co-culture (Fig. 5b). Similar effects of the myofi-
broblasts on morphology (Supplementary Fig. S4) and cell
counts (Supplementary Fig. S5) in the presence of 10 nM
DHT were observed for the other two AR-expressing EAC
cell lines, JH-AR and OE19-AR. Increasing the DHT
concentration to 100 or 1000 nM resulted in complete
inhibition of OE33-AR proliferation in direct co-culture
with the myofibroblasts (p\ 0.0001) (Supplementary
Fig. S6). The addition of enzalutamide to cultures blocked
the DHT mediated inhibition of OE33-AR growth in
monoculture (p\ 0.0001), but did not significantly alter
the outcome of direct co-culture with the myofibroblasts
(p = 0.544) (Fig. 5c).
Fig. 5 Morphology and growth
of OE33-AR in direct co-culture
with fibroblasts. a Fluorescent
micrographs of OE33-AR
(green) in monoculture or in
direct co-culture with NFFs
(blue) or PShTert
myofibroblasts (red) treated
with vehicle or 10 nM DHT for
6 days, with the medium
replaced every 48 h. Scale bar is
75 lM. b Cell counts of OE33-
AR grown for 6 days with
vehicle or 10 nM DHT in
monoculture or direct co-culture
with NFFs or PShTert
myofibroblasts. c Cell counts of
OE33-AR grown for 6 days
with vehicle or 10 nM DHT,
with or without 15 lM
enzalutamide, in monoculture or
direct co-culture with PShTert
myofibroblasts. Cell count data
are the mean ± SD of three
replicates from a representative
experiment
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Translocation of AR in Direct Co-cultures
We investigated whether nuclear translocation of AR was
altered in OE33-AR in direct co-culture. The results in
Fig. 6 show that the OE33-AR treated with vehicle, in
either monoculture or direct co-culture, had mild AR
immunoreactivity in the cytoplasm and weak immunore-
activity in the nucleus, consistent with a lack of AR acti-
vation. With 10 nM DHT, there was complete
translocation of AR to the nucleus and no AR in the
cytoplasm of OE33-AR in monoculture or direct co-culture
with NFFs. In contrast, there was a DHT dose-dependent
distribution of AR in OE33-AR directly co-cultured with
the myofibroblasts. With 10 nM DHT, there was moderate
immunoreactivity in the nucleus, and mild to moderate
immunoreactivity in the cytoplasm. With 100 nM DHT,
there was complete nuclear translocation in about 50% of
OE33-AR, with mild cytoplasmic and moderate nuclear
immunoreactivity in remaining cells, and with 1000 nM
DHT, there was complete nuclear translocation in all cells.
The finding of both nuclear and cytoplasmic AR in OE33-
AR directly co-cultured with myofibroblasts was similar to
our findings in EAC resection samples where AR was
expressed in both the nucleus and cytoplasm in the
majority of tissues.
DHT Induced Expression of Androgen-Responsive
Genes in Co-cultures
We next measured the effect of 10 nM DHT on the tran-
script levels of the androgen-responsive genes FKBP5,
HMOX1 (heme oxygenase 1) and NDRG1 (N-myc down-
stream regulated 1) in OE33-AR in monoculture or direct
co-culture. The OE33-ARs (GFP-positive) were sorted
from NFFs (GFP-negative) or myofibroblasts (RFP-posi-
tive) in the direct co-cultures. The results in Fig. 7a show
that the change in expression induced by DHT, induction, or
repression was similar in the monoculture and co-cultures,
Fig. 6 Nuclear translocation of AR induced by DHT in OE33-AR in
direct co-culture with fibroblasts. Fluorescent micrographs of OE33-
AR grown for 6 days in monoculture or direct co-culture with
PShTerts with vehicle or 10, 100, or 1000 nM DHT, or in direct co-
culture with NFFs with vehicle or 10 nM DHT. Cells were labeled
with rabbit antihuman AR polyclonal IgG (clone N-20; 1 lg/mL in
1.5% goat serum) followed by secondary antibody Alexa Fluor 568
goat anti-rabbit IgG (2 lg/mL in 1.5% goat serum) and DAPI (1 lg/
mL). Merged channel images were captured using a Zeiss confocal
LSM 700 microscope. Scale bar is 75 lM
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although the extent of the change varied. This suggests that,
although DHT did not inhibit OE33-AR growth in direct co-
culture with myofibroblasts, there was still a change in the
expression of androgen-responsive genes.
This response of OE33-AR to DHT in direct co-culture
with myofibroblasts was also confirmed in two other AR-
expressing EAC cell lines, JH-AR and OE19-AR (Supple-
mentary Fig. S7). Co-cultured cells remained unsorted since
the expression of androgen-responsive genes in myofi-
broblasts did not increase with DHT (FKBP5, p = 0.437;
HMOX1, p = 0.244; NDRG1, p = 0.339) (Supplementary
Fig. S8). Unsorted OE33-AR co-cultures were used for
comparison. FKBP5 was upregulated with 10 nM DHT in
both monoculture and direct co-culture with myofibroblasts
for all three AR-expressing EAC cell lines. HMOX1 and
NDRG1 had limited androgen responsiveness for JH-AR, as
shown previously in Supplementary Fig. S3. OE19-AR
showed upregulation of HMOX1 and downregulation of
NDRG1 with DHT in both monoculture and direct co-cul-
ture with myofibroblasts. While the use of unsorted cells
may have reduced the significance of these changes, the
results suggest that, for all three AR-expressing EAC cell
lines, the myofibroblast blocked the growth inhibition but
not the gene expression induced by DHT in monoculture.
To confirm that changes in gene expression were
mediated through the AR signaling pathway, the anti-
androgen enzalutamide was used. The results in Fig. 7b
show the effect of enzalutamide on FKBP5 expression in
OE33-AR directly co-cultured with myofibroblasts with
10 nM DHT. Again, we measured expression in unsorted
cells because FKBP5 expressed by myofibroblasts did not
increase with DHT. Enzalutamide reduced the expression
both in monoculture (tenfold; p = 0.0002) and in direct co-
culture with the myofibroblasts (17-fold; p = 0.0003),
indicating that FKBP5 upregulation was mediated through
AR. This confirms that, in co-culture conditions where
DHT did not inhibit proliferation, DHT was still functional
in regulating the expression of androgen-responsive genes
through the AR signaling pathway.
Discussion
We have previously reported that nuclear localization of
AR and/or expression of the androgen-responsive gene
FKBP5 was associated with decreased survival in EAC,
suggesting a role for androgens in this cancer [15]. Here we
have extended that study to show that EAC resection tis-
sues with a higher percentage of FKBP5 positive cells also
had a higher proliferation index, showing a positive rela-
tionship between androgen signaling and cancer cell
growth. We have investigated the effects of androgen on
Fig. 7 Effect of co-culture with fibroblasts on DHT induced expres-
sion of androgen-responsive genes in OE33-AR. a The expression of
FKBP5, HMOX1, and NDRG1 in OE33-AR grown for 6 days with
vehicle or 10 nM DHT in monoculture or direct co-culture with NFFs
or PShTert myofibroblasts. Expression was normalized to the
reference gene ACTB and graphed relative to expression with
vehicle. Data are the mean ± SD. b Expression of FKBP5 in OE33-
AR grown for 6 days with vehicle or 10 nM DHT, with or without
15 lM enzalutamide, in monoculture or direct co-culture with
PShTert myofibroblasts
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the behavior of AR-expressing EAC cell lines in vitro. The
three EAC cell lines that we stably transduced with full-
length human AR cDNA were responsive to androgen, as
shown by DHT induced nuclear localization of the recep-
tor, and dose-dependent changes in cell proliferation,
morphology, and gene expression. The commonly used
concentration of DHT, 10 nM, markedly altered the
expression of androgen-responsive genes, but completely
inhibited cell proliferation by inducing cell cycle arrest and
senescence, which appeared to be inconsistent with our
findings in patient tissues of increased proliferation and
upregulation of androgen-responsive gene expression. We
then found that lower concentrations of DHT around the
IC50 allowed proliferation and induced significant,
although smaller, changes in the expression of androgen-
responsive genes. We also found that in direct co-culture
with an immortalized myofibroblast cell line, PShTert, the
growth inhibitory effect of 10 nM of DHT was largely
nullified, but the effect on expression of androgen-re-
sponsive genes was unaltered.
Studies of the effect of androgens on cell proliferation
have generated conflicting results. Inhibition of prolifera-
tion has been reported often, in normal and cancer cell lines
from a range of tissues, either naturally expressing or
transduced with AR [25–40]. No change or an increase in
cell proliferation has also been reported [34, 40–43]. Why
androgens in some cells increase and in others decrease
proliferation is unclear. Many of the reported studies only
used a single concentration of DHT, most commonly
10 nM. When dose–response studies have been reported,
the IC50 for DHT inhibition of proliferation has been of the
same order as we measured [29, 30, 33, 40]. Our finding
that growth inhibition was associated with cell cycle arrest
and the induction of senescence is also consistent with
other reports [30, 44–46].
This is the first comprehensive study of the expression
of androgen-responsive genes across a range of DHT
concentrations, in parallel with measurements of prolifer-
ation, in AR-expressing cells that are growth inhibited by
DHT. We showed a DHT dose-dependent alteration of the
expression of these genes. This could be measured from
DHT concentrations around the IC50, significantly lower
than the 10 nM most commonly used for in vitro studies
[27, 47, 48]. Most reported studies use a single dose of
DHT given at the start of the culture period. Single doses
around the IC50 resulted in small, but significant, changes
in the expression of the androgen-responsive genes. Daily
replenishment of the DHT increased the magnitude of the
gene expression response without significantly altering
proliferation. Daily replenishment, compared to a single
dose, would be expected to more closely mimic the
delivery of hormone in vivo. Our observations that DHT
concentrations around the IC50 were sufficient to increase
FKBP5 expression and allow proliferation were consistent
with the association between FKBP5 and Ki-67 expression
we measured in patient EAC resection specimens, which
suggest our in vitro findings are clinically relevant.
The tumor microenvironment is an important determi-
nant of the response of cancer cells to molecules such as
hormones and drugs [24, 49]. We therefore examined the
effect of androgens on our AR-expressing EAC cell lines in
direct co-culture with fibroblasts, the primary cellular
component of the microenvironment. The PShTert myofi-
broblast line, an immortalized activated fibroblast line
which has properties typical of cancer-associated fibroblasts
[20–22, 50–53], allowed the growth of AR-expressing EAC
cells at concentrations of DHT that inhibited the growth of
cells in monoculture, without affecting the gene expression
changes induced by DHT in monoculture. These are the first
reported studies of EAC cell lines in co-culture with
fibroblasts or myofibroblasts. There are a number of studies
of the effect on prostate cancer cell lines of co-culture with
PShTert myofibroblasts, but none have investigated how
fibroblasts affect the inhibition of cancer cell proliferation
by androgen [20–22]. In our study, the myofibroblasts do
not appear to be depleting androgen from the culture
medium since there are still changes in the expression of
androgen-responsive genes that can be blocked by the anti-
androgen enzalutamide. This suggests that the microenvi-
ronment has the potential to modify the response of AR-
expressing EAC cells to androgen in vivo. The mechanisms
for this are unknown, warranting further investigation that
may lead to new targets for manipulating the progression of
EAC and possibly other androgen-responsive cancers.
This is the first study to show a positive association
between androgen signaling and cancer cell proliferation in
EAC, and that AR-expressing EAC cell lines respond to
androgens in vitro. Proliferation of AR-expressing EAC
cells in monoculture was inhibited by higher concentra-
tions of DHT. Our in vitro findings suggest that, in cancer
tissues in vivo, AR-expressing EAC cells at lower con-
centrations of DHT, or in the presence of activated
fibroblasts in the microenvironment, would proliferate and
DHT would alter the expression of androgen-responsive
genes. Our findings are consistent with a role for androgen
signaling in EAC.
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